Cargando…
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization
BACKGROUND: EGFR targeting is currently the main treatment strategy for metastatic colorectal cancer (mCRC). Results of different clinical trials show that patients with wild-type KRAS and BRAF benefit from anti-EGFR monoclonal antibodies (moAbs) cetuximab (CTX) or panitumumab. Unfortunately, despit...
Autores principales: | Romaniello, Donatella, Gelfo, Valerio, Pagano, Federica, Ferlizza, Enea, Sgarzi, Michela, Mazzeschi, Martina, Morselli, Alessandra, Miano, Carmen, D’Uva, Gabriele, Lauriola, Mattia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903543/ https://www.ncbi.nlm.nih.gov/pubmed/35236282 http://dx.doi.org/10.1186/s11658-022-00319-7 |
Ejemplares similares
-
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
por: Romaniello, Donatella, et al.
Publicado: (2023) -
Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression
por: Ferlizza, Enea, et al.
Publicado: (2023) -
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies
por: Miano, Carmen, et al.
Publicado: (2022) -
Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies
por: Gelfo, Valerio, et al.
Publicado: (2019) -
Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation
por: Sgarzi, Michela, et al.
Publicado: (2023)